Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.

ABSTRACT:

Background

The treatment of refractory nephrotic syndrome (RNS) is full of challenges and the role of rituximab (RTX) is not well-established, thus this study aims to demonstrate the role of RTX in RNS.

Methods

This was a multicenter retrospective study of all adult patients receiving RTX for RNS. Patients enrolled were divided into two groups according to pathological pattern: 20 patients as a group of podocytopathy (including minimal change disease [MCD] and focal and segmental glomerulosclerosis [FSGS]), and 26 patients as membranous nephropathy (MN) group. The remission rate, relapse rate, adverse effects, and predictors of remission were analyzed.

Results

A total of 75 patients received RTX for RNS and 48 were available for analysis after exclusion criteria. No s

SUBMITTER: Ma X 

PROVIDER: S-EPMC10367573 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature